Tirzepatide in the Treatment of Endometrial Cancer

What Was Tested

The trial (phase 2) is built around Tirzepatide for endometriosis.

This study is looking for a better way to treat pre-cancer or early-stage cancer in the lining of the uterus in women who are also overweight.

Everyone in the study will receive the standard treatment, a Progesterone IUD (LNG-IUD).

This device is put in the uterus and releases hormones to help fight the disease.

It had 1 arm (groups): LNG-IUD + Tirzepatide (experimental).

This is a multicenter, open-label, prospective, single-arm phase II pilot trial using a sequential design to evaluate the addition of tirzepatide to LNG-IUD in women with obesity and premalignant or early-stage endometrioid endometrial pathology.

The registry classes the interventions as device and drug.

More on the Plan

This study is looking for a better way to treat early-stage uterine problems in women who are also overweight.

These problems are called pre-cancer (EIN) or early cancer of the uterus.

The standard treatment the researchers already use is a device called the LNG-IUD, which is placed in the uterus and releases hormones.

This device helps many women avoid surgery and keep their ability to have children, but it doesn't always work well for women who are overweight.

Who Took Part

Enrollment: 30 planned participants were the target.

It was open to women only aged from 18 years up to 99 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

The full record lists 13 inclusion and 0 exclusion criteria.

How the Study Was Run

It was run as a single-group and open-label study.

Being open-label, the Tirzepatide study did not mask who received what.

Everyone received the same intervention, so there was no separate comparison group inside the trial.

It started in 2026-06-01 with completion listed for 2028-01.

Its stated primary purpose is treatment.

What Was Measured

Researchers chose this as the main measure: Quality of Life Quality of life will be measured through PROMs at the time points listed below for explorative purposes.

What This Means in Plain Language

Put simply, this is a phase 2 trial of Tirzepatide in 30 people with endometriosis.

Its size is small, so on its own it can only give an early look.

Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Tirzepatide compound page, Endometriosis research.